## **Core Concept**
Zollinger-Ellison syndrome is a rare disorder characterized by excessive gastric acid production due to high levels of gastrin, often caused by a gastrinoma. The management involves reducing gastric acid secretion.

## **Why the Correct Answer is Right**
The correct answer, **Omeprazole**, is a proton pump inhibitor (PPI) that effectively reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells. This mechanism is crucial in managing conditions like Zollinger-Ellison syndrome where there is an overproduction of gastric acid. PPIs are considered the drug of choice for this condition due to their potent acid-suppressing effects.

## **Why Each Wrong Option is Incorrect**
- **Option A: Ranitidine** - This is an H2 receptor antagonist that also reduces gastric acid production but is less potent than PPIs like omeprazole. It is not the first choice for managing Zollinger-Ellison syndrome.
- **Option B: Sucralfate** - This drug works by forming a protective barrier over ulcers, promoting healing, but it does not reduce acid production and is not suitable for managing Zollinger-Ellison syndrome.
- **Option D: Misoprostol** - This is a synthetic prostaglandin E1 analogue that reduces gastric acid secretion but is primarily used for preventing NSAID-induced gastric ulcers and is not the first-line treatment for Zollinger-Ellison syndrome.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that in Zollinger-Ellison syndrome, **proton pump inhibitors (PPIs) are the mainstay of treatment** because they can effectively control acid hypersecretion. High doses of PPIs may be required, and monitoring of the patient's response is crucial.

## **Correct Answer:** . Omeprazole